

Press release
29 December 2025

Curasight A/S resolves to issue a convertible loan note

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM DANISH LAW. SEE THE "IMPORTANT INFORMATION" SECTION AT THE END OF THIS PRESS RELEASE.

Curasight A/S ("Curasight" or the "Company" – TICKER: CURAS) has, as previously communicated on 12 December 2025, entered into a loan agreement with Fenja Capital II A/S ("Fenja Capital", the "Lender") regarding a loan facility. Today, the Board of Directors resolved to issue a convertible loan note to Fenja Capital based on the authorization granted by the Extraordinary General Meeting held earlier today

Curasight has as communicated on 12 December 2025 entered into a loan agreement with Fenja Capital regarding a loan facility conditional upon an authorizing being granted by the general meeting of the Company to the Board of Directors to issue the relevant convertible loan instrument to Fenja. Based on the authorization granted by the Extraordinary General Meeting held earlier today, the Board of Directors of Curasight has resolved to issue a convertible loan note to Fenja Capital.

The total loan facility is divided into two tranches. The first tranche amounts to DKK 25 million and will be structured as a convertible loan (the "Convertible Loan"), of which DKK 10 million represents a refinancing of the existing loan and DKK 15 million will be disbursed following today's resolution to issue the Convertible Loan. The second tranche amounts to DKK 15 million and may be drawn in Q2 2026.

The loan facility carries a setup fee of 5 percent on the total facility amount. Interest on drawn amounts accrues at 1.25 percent per started 30-day period, while interest on undrawn amounts accrues at 0.4 percent per started 30-day period. The loan facility has a maturity date of 2026-12-29, with a total convertible size of DKK 25 million. The conversion price is set at 125 percent of the subscription price in the directed Issue. Upon conversion, a maximum of 2,506,266 new shares may be issued in the Company, corresponding to an increase in the share capital of SEK 125,313.30 and a dilution of approximately 4.97 percent.

Advisors

Curasight has engaged Sedermera Corporate Finance AB as financial adviser and DLA Piper as the Company's legal advisor.

Press release
29 December 2025

For more information about the directed issue, please contact:

Sedermera Corporate Finance AB

Phone: +46 (0)40 615 14 10

E-mail: cf@sedermera.se

www.sedermera.se

For further information about the Company, please contact:

Ulrich Krasilnikoff, CEO, Curasight A/S

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

About Curasight

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.